A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF
A PHASE 3 STUDY IN INDIA TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
The purpose of this phase 3 multicenter, double-blinded, placebo-controlled study in India is to learn about the safety and immunogenicity of RSVpreF in adults.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Pfizer CT.gov Call Center
- 전화번호: 1-800-718-1021
- 이메일: ClinicalTrials.gov_Inquiries@pfizer.com
연구 장소
-
-
Andhra Pradesh
-
Visakhapatnam, Andhra Pradesh, 인도, 530002
- 모병
- King George Hospital
-
-
Karnataka
-
Bangalore, Karnataka, 인도, 560060
- 모병
- BGS Global Institute of Medical Sciences (BGSGIMS)
-
Bangalore, Karnataka, 인도, 560085
- 모병
- Radhakrishna Multispeciality Hospital and IVF Center
-
Belagavi, Karnataka, 인도, 590001
- 모병
- Belagavi Institute of Medical Sciences - Belagavi
-
-
Maharashtra
-
Nashik, Maharashtra, 인도, 422003
- 모병
- Suyog Hospital
-
Pune, Maharashtra, 인도, 411043
- 모병
- Bharati Vidyapeeth {Deemed to be University) Medical College Hospital & Research Centre
-
-
National Capital Territory of Delhi
-
Dwarka, National Capital Territory of Delhi, 인도, 110075
- 모병
- Aakash Healthcare Private Limited
-
New Delhi, National Capital Territory of Delhi, 인도, 110060
- 모병
- Sir Ganga Ram Hospital
-
New Delhi, National Capital Territory of Delhi, 인도, 110029
- 모병
- All India Institute Of Medical Sciences
-
-
Rajasthan
-
Jaipur, Rajasthan, 인도, 302039
- 모병
- Maharaja Agrasen Superspeciality Hospital
-
-
Tamil Nadu
-
Chengalpattu, Tamil Nadu, 인도, 603203
- 모병
- SRM Medical College Hospital and Research Centre - Kattankulathur
-
Kelambākkam, Tamil Nadu, 인도, 603103
- 모병
- Chettinad Hospital and Research Institute
-
-
West Bengal
-
Kolkata, West Bengal, 인도, 700020
- 모병
- Institute of Post Graduate Medical Education & Research, SSKM Hospital
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria:
- Participants ≥18 years of age at Visit 1.
- Participants who are ambulatory and live independently in the community.
- Participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.
- Applicable to participants 18 through 59 years of age: Participants who are healthy or have stable preexisting diseases. These participants are considered at high risk of RSV disease by having at least 1 reportable stable chronic medical condition(s) that belongs to 1 or more of the following:
- Chronic heart disease (ie, coronary artery disease, heart failure, or congenital heart disease)
- Chronic lung disease (ie, COPD, emphysema, asthma, interstitial lung disease, or cystic fibrosis)
- Nongestational diabetes mellitus type 1 or type 2
- Severe obesity (body mass index [BMI] ≥40 kg/m2)
- Chronic liver disease (ie, cirrhosis)
- Chronic kidney disease (not including end-stage renal disease with or without dialysis)
- Chronic neurological disease that causes impaired airway clearance or respiratory muscle weakness (ie, poststroke dysphagia, amyotrophic lateral sclerosis, or muscular dystrophy)
- Chronic hematologic disease (ie, sickle cell disease or thalassemia)
Note: A chronic medical condition for this study is defined as:
- Duration ≥6 months.
- Requires regular medical follow-up or ongoing prescribed medication or hospitalization in the previous year.
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in the protocol.
Key Exclusion Criteria:
- Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s) or any related vaccine.
- Prior history of any subtype of Guillain-Barré syndrome of any etiology.
- Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study.
- Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
- Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids, or radiotherapy, eg, for cancer or an autoimmune disease, from 60 days before study intervention administration or planned receipt throughout the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: Placebo
Placebo |
Placebo |
|
실험적: RSVpreF
RSVpreF Vaccine |
RSVpreF Vaccine |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titers (GMT)
기간: Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
기간: Before vaccination, 1 month after vaccination
|
Before vaccination, 1 month after vaccination
|
|
|
NTs for RSV A and RSV B expressed as seroresponse rate
기간: 1 month after vaccination
|
1 month after vaccination
|
|
|
Proportion of participants reporting local reactions within 7 days following investigational product administration
기간: Within 7 days
|
Describe local reactions following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting systemic events within 7 days following investigational product administration
기간: Within 7 days
|
Describe systemic events following investigational product administration |
Within 7 days
|
|
Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration
기간: 1 month after vaccination
|
Describe AEs occurring through 1 month following administration of investigational product |
1 month after vaccination
|
|
Percentage of participants reporting serious adverse events (SAEs) throughout the study
기간: 3 months after vaccination
|
Describe SAEs through 3 months following administration of investigational product |
3 months after vaccination
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Pfizer CT.gov Call Center, Pfizer
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
기타 연구 ID 번호
- C3671040
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .